---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076044"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2026-06-22T10:50:13+00:00"
generated_at: "2026-06-22T10:55:06.888353+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# uniQure reports AMT-260 Phase I/IIa data: 3/6 patients saw 79-100% seizure reduction; no SAEs

## Summary
- Three of six patients in low-dose cohort achieved 79% to 100% decline in disabling seizures (months 4-6).
- Remaining three patients had variable changes: -33% to +36% from baseline.
- No serious adverse events related to AMT-260 or surgery; all AEs mild/moderate, headache most common (N=2).
- Enrollment ongoing for second, higher-dose cohort (3x10¹² gc/mL), expected completion mid-2026; updated results H1 2027.

## SEC filing metadata
- accession: 0001104659-26-076044
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2026-06-22T10:50:13+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/0001104659-26-076044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000110465926076044/qure-20260619x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076044
- JSON: https://secwatch.observer/filing/0001104659-26-076044.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.